Description
The study reveals a novel pathway where PGC-1α negatively regulates dopaminergic identity through Pitx3 and BDNF in mice. Validating this pathway in human disease is essential for translating these findings to clinical interventions.
Gap type: open_question Source paper: Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. (2012, PloS one, PMID:23145024)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:40.743690+00:00”, “resolution_summary”: “Resolved by hypothesis h-var-9c0368bb70: Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization. Supporting evidence includes debate sess_SDA-2026-04-13-gap-pubmed-20260410-171850-e91bcc0d.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-var-9c0368bb70”, “title”: “Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization”, “score”: 0.222, “reason”: “17 token overlaps; entity overlap: bdnf”, “analysis_id”: “SDA-2026-04-03-26abc5e5f9f2”, “target_gene”: “BDNF”, “target_pathway”: “Hippocampal neurogenesis and synaptic plasticity”, “disease”: “Alzheimer’s disease”, “composite_score”: 0.885388, “confidence_score”: 0.76, “status”: “promoted”, “pubmed_evidence_ids”: [“16844302”, “23384605”, “23620781”, “23746839”, “25220633”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-171850-e91bcc0d”, “title”: “PGC-1α is known to enhance mitochondrial function and antioxidant responses, yet overexpression increased susceptibility to MPTP-induced neuronal death. This contradicts the expected neuroprotective role and challenges PGC-1α as a therapeutic target in PD.\n\nGap type: contradiction\nSource paper: Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. (2012, PloS one, PMID:23145024)”, “score”: 0.85, “reason”: “17 token overlaps; entity overlap: mptp, pgc-, pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-171850-e91bcc0d”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071_20260414-013429”, “title”: “The authors explicitly state that the effects of these novel genes (MATR3, CHCHD10, TBK1, TUBA4A, NEK1, C21orf2, and CCNF) have not yet been investigated in animal models. This is critical for understanding pathogenic mechanisms and translating findings to clinical practice.\n\nGap type: open_question\nSource paper: Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. (2018, The Lancet. Neurology, PMID:29154141)”, “score”: 0.402, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-165527-8256a071”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e”, “title”: “While RGS6 deficiency causes Parkinson’s-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.\n\nGap type: open_question\nSource paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)”, “score”: 0.349, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e”, “title”: “While RGS6 deficiency causes Parkinson’s-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.\n\nGap type: open_question\nSource paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)”, “score”: 0.349, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-193701-11582758_20260416-035652”, “title”: “The abstract reveals contradictory evidence where clusterin is proposed as a protective chaperone protein, yet knockout studies show it exacerbates neuronal death in hypoxia-ischemia. This fundamental contradiction undermines therapeutic targeting strategies.\n\nGap type: contradiction\nSource paper: Clusterin. (None, None, PMID:11906815)”, “score”: 0.348, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-193701-11582758”, “quality_score”: 0.72, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}